Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Recommendation of Moderate Buy from Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) has been given a consensus rating of “Moderate Buy” by the six brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among […]

Related Keywords

Adrienne Farid ,Century Therapeutics Company Profile ,Canaccord Genuity Group ,Blackrock Inc ,Hermes Inc ,Century Therapeutics Inc ,Securities Exchange Commission ,Nasdaq ,Vanguard Group Inc ,Century Therapeutics ,Get Free Report ,Marketbeat Ratings ,Genuity Group ,Therapeutics Stock Down ,Exchange Commission ,Partners Management ,State Street Corp ,Street Corp ,Get Free ,Century Therapeutics Daily ,Nasdaq Ipsc ,Aipsc ,Medical ,Ratings ,Consensus ,